The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.

Appropriate Patient Criteria:

• Patient is eligible to receive a Boston Scientific TAXUS Stent

Inappropriate Patient Criteria:

• Known sensitivity to paclitaxel.
• Known allergy to stainless steel.
• Patients in whom antiplatelet and / or anticoagulant therapy is contraindicated.
• Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or delivery device.
• Patients with unresolved vessel thrombus at the lesion site.
• Patients with coronary artery reference vessel diameters less than 2.5 mm or greater than 3.75 mm.
• Patients with lesions located in the left main coronary artery, ostial lesions, or lesions located at a bifurcation.
• Patients with diffuse disease or poor overflow distal to the identified lesions.
• Patients with tortuous vessels in the region of the obstruction or proximal to the lesion.
• Patients with a recent acute myocardial infarction where there is evidence of thrombus or poor flow.